Veranex’s Post

Raising the bar on infection prevention—and raising money to get to FDA clearance and US launch. We're honored by what Venture Capital Post said in their recent feature of Hylomorph, "Just as Google and Apple push each other to innovate, Hylomorph is driving impactful change in the medical device industry. Positioned alongside other industry leaders, Hylomorph is taking a leading role in addressing surgical infections in cardiology and beyond. By focusing on both current and future surgical needs, the team at Hylomorph aims to not only tackle today's challenges but also anticipate tomorrow's." If you're an #investor looking for an ambitious company aiming to become a global leader in infection prevention, provide low-risk, short-term returns and long-term opportunity, we want to talk to you during #LSIEurope24. Please use the LSI partnering app to find a time that works for you: https://lnkd.in/de-k8N-z. You can also use a link to our Bookings page in the comments below. #hylomorph #infectionprevention #healthcare #medtech #healthcareinnovation

We are proud to announce that we have raised £80 million ($105 million) in an oversubscribed Series B #financing led by Sofinnova Partners, alongside Forbion, Gilde Healthcare, British Patient Capital, and founding #investor Syncona Limited . This funding will be used to accelerate the development of our novel podocyte-targeting AAV #GeneTherapy platform, which has the potential to transform the lives of the 840 million people globally with kidney diseases. This includes advancing our lead programme, PS-002, which targets IgA Nephropathy (IgAN), a common, chronic kidney disease affecting young adults, towards a Phase I/II #ClinicalTrial. There are currently no therapeutic options to stop disease progression, nor a cure, and nearly one third of IgAN patients will go on to lose their kidney function within five years and require a kidney transplant or dialysis. We’re delighted to have such a high-quality syndicate of investors who have the expertise and the commitment to move this platform into clinical development, and we look forward to working with them. To learn more, read the full press release here: https://lnkd.in/eaSU6qnU #Biotech #HealthcareInnovation #KidneyDisease #SeriesB #Fundraise

Life science founders, time is running out! The deadline to apply for Invest In Cures Virtual Partnering Event is January 23rd. Don't miss out on the chance to meet early stage investors focused on specific rare disease indications. Apply Here: https://lnkd.in/gcFBfWy9 #InvestInCures #VirtualPartneringEvent #LifeScienceFounders #RareDiseaseIndications

Every year, I try to write at least one essay about cystic fibrosis for CF Awareness Month. This year, I was honored to be invited by Emily Kramer-Golinkoff to write a blog for Emily's Entourage series. In this blog, I reflected on my sister's life in the context of how different my life has been since I started Trikafta, and how I wish this was the future she had received. It was tragically not, and that's exactly why we must cure CF because it's the future we all deserve. #CFAwarenessMonth Link to the blog: https://lnkd.in/eE8ZEmQT Link to my essay from last year: https://lnkd.in/ehWA-zh2

Another interesting case study: During indication prioritization/ in-licensing projects, clients often are unwilling to go for orphan indications with a prevalence below 3k US patients (commercial potential concerns - which makes a huge cut in the orphan disease space!). On Friday, September 20, Zevra has received approval for MIPLYFFA™ for Niemann-Pick Disease Type C. During their call, Zevra indicated 900 people in the US living with NPC and only 300-350 currently diagnosed and treated (mostly in centers of excellence). Wholesale acquisition cost ranging from $40,000 per month to $106,000 per month depending on dosage (we do not have information on GtN). Curious to see how this will all translate in peak sales down the line (how many more patients will they be able to reach?). We need to find more solutions to foster innovation for ultra-rare diseases (and I leave the discussion around PRV for another post…)  #RareDisease #NPC Zevra Therapeutics https://lnkd.in/e8ZShXnU

Watch a sneak peek into this #ACRP2024 session where Heidi Kirkpatrick from Merck will guide attendees through the critical elements for a successful clinical trial. Uncover strategies to mitigate deviations, minimize queries, and, ideally, avoid violations altogether. Plan to attend in Anaheim > https://bit.ly/4aOqpJb #GoForIt #GoForEducation #ClinicalTrials #ClinicalResearch #ClinicalResearchStudy #SiteManagement #OncologyTrial

We're excited to share our new slide deck covering the most recent developments and key timelines for PFAS-related personal injury cases. With the resolution of water contamination cases, the focus is now on Tier 1 injury cases such as kidney and testicular cancer. 🔍 What's Inside: • Bellwether trial schedule and key dates • Strategic focus for legal teams • Important deadlines for expert reports and Daubert motions • Broader context and recent regulatory updates 📅 Key Dates to Watch: • Discovery completion for kidney and testicular cancer cases: June 18, 2024 • Case selections for trial: July 16, 2024 • Fact discovery for thyroid and ulcerative colitis: October 16, 2024 • Daubert Motions briefing completion: April 17, 2025 Stay informed and prepare for the upcoming milestones in PFAS litigation. #PFAS #MassTort #LitigationUpdate #BlueSkyLegal

Join Taylor Lipsich from PatientWing as she explores 'How Building Trust with Rare Disease Patients Accelerates Trial Enrollment' at the 20th Biopharma Clinical Trials Nexus in San Diego. Don't miss this insightful discussion! #NEXUSconference #Patientwing #BioPharmaNexus #raredisease

🚀 Exciting Webinar Alert! 🚀 We’re thrilled to announce our upcoming webinar in collaboration with Hanson Wade Intelligence! 🎉 Join Rachel Hourigan and Joe Moss for "Inflammatory Bowel Disease: A Comprehensive Analysis of Drug and Market Trends" on June 26, 2024. Don't miss out on this comprehensive analysis! Register now 👇 https://ter.li/1rh5bs Dive deep into the intricate landscape of IBD, exploring key drug modalities like JAK and TNF alpha inhibitors, and S1P modulators. We'll review recent approvals and discontinuations, discuss adverse events from trials, and highlight emerging companies and notable deals in the market. Plus, get the latest insights on market trends, growth drivers, and leading players in the IBD sector. #InflammatoryBowelDisease #IBD #JAKinhibitors #TNFalphas #S1Preceptors #DrugTrends #MarketAnalysis

#EarningsWithMC | 📉 Wockhardt Q1: Net loss narrows to ₹16 Cr, with income rising to ₹769 Cr from ₹658 Cr YoY. 💊📈 Know more🔽 https://lnkd.in/dT6y3Zg6 #Wockhardt #Earnings #NetProfit